^
    CANCER:

    Mantle Cell Lymphoma





    Show legend
    Group by Gene:
    Include preclinical:

    pirtobrutinib
    ibrutinib
    		0
    BTK inhibitor
    acalabrutinib
    zanubrutinib
    orelabrutinib
    TG-1701
    1
    CD19-targeted CAR-T immunotherapy
    brexucabtagene autoleucel
    lisocabtagene maraleucel
    2
    Bcl2 inhibitor, BTK inhibitor
    venetoclax + ibrutinib
    ibrutinib + rituximab
    		3
    BTK inhibitor, CD20 inhibitor
    rituximab + zanubrutinib
    rituximab + acalabrutinib
    4
    mTOR inhibitor
    temsirolimus
    5
    Proteasome inhibitor, CD20 inhibitor
    rituximab + bortezomib
    6
    Proteasome inhibitor
    bortezomib
    carfilzomib
    7
    CD20 inhibitor
    rituximab
    8
    DNA replication inhibitor
    bendamustine
    9
    Bcl2 inhibitor
    venetoclax
    10
    Bcl2 inhibitor, CD20 inhibitor
    venetoclax + rituximab
    11
    PI3Kδ inhibitor
    INCB50465
    12
    Bcl2 inhibitor, BTK inhibitor, CD20 inhibitor
    venetoclax + ibrutinib + rituximab
    venetoclax + obinutuzumab + zanubrutinib
    13
    ROR1 inhibitor, BTK inhibitor
    ibrutinib + UC-961
    14
    CD3 agonist, ROR1 inhibitor
    NVG-111
    BOVen
    R-DHAP
    VR-CAP
    R-DHAX + R-CHOP
    R-DHAC + R-CHOP
    		15
    Chemotherapy
    R-CHOP + R-DHAP
    R-Maxi-CHOP
    R-CHOP
    R-GemOx
    R-CVAD
    ViPOR
    R-DHAX
    16
    T-lymphocyte cell therapy
    T-lymphocyte cell therapy
    17
    Immunotherapy
    Immunotherapy
    18
    TNFα inhibitor, Immunotherapy, IL-12 inhibitor, IL-6 inhibitor
    Immunotherapy + lenalidomide
    19
    TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor
    lenalidomide
    20
    TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor, BTK inhibitor, CD20 inhibitor
    ibrutinib + rituximab + lenalidomide
    rituximab + lenalidomide + acalabrutinib
    21
    TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor, CD20 inhibitor
    rituximab + lenalidomide
    22
    PDGFR antagonist, mutant c-KIT inhibitor, CSF-1R inhibitor
    avapritinib
    23
    CD3 agonist, CD20 inhibitor
    epcoritamab-bysp
    EX103
    24
    TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor, Bcl2 inhibitor, CD20 inhibitor
    venetoclax + rituximab + lenalidomide
    25
    PIK3CA inhibitor, PI3Kδ inhibitor
    copanlisib
    26
    PLK1 inhibitor
    NBL-001
    27
    PLK1 inhibitor, PIK3CA inhibitor, PI3Kδ inhibitor
    copanlisib + NBL-001
    28
    CDK4 inhibitor, CDK6 inhibitor
    palbociclib
    29
    PARP inhibitor
    olaparib
    30
    γ-secretase inhibitor
    Compound E
    31
    DNA synthesis inhibitor
    fludarabine IV
    32
    DNA synthesis inhibitor, DNA-directed DNAP inhibitor
    cytarabine
    33
    ERK2 inhibitor, ERK1 inhibitor
    ASN007
    34
    BRD4 inhibitor, PI3K inhibitor, BTK inhibitor
    SRX3262
    35
    MEK inhibitor, Bcl2 inhibitor
    venetoclax + trametinib
    36
    DNA polymerase theta inhibitor
    VP-006
    ART558
    37
    DNA replication inhibitor, CD19-targeted antibody-drug conjugate
    IKS03
    38
    Alkylating agent, DNA repair enzyme inhibitor
    LP-284
    39
    ROR1-targeted antibody-drug conjugate, Microtubule inhibitor
    MK-2140
    40
    ROR1-targeted CAR-T immunotherapy
    ONCT-808
    41
    Casein kinase I epsilon inhibitor, PI3Kδ inhibitor, BTK inhibitor, CD20 inhibitor
    umbralisib + ublituximab-xiiy + TG-1701
    No biomarker
    TP53 mutation
    TP53 deletion
    TP53 overexpression
    ABCB1 2677G>T/W
    CCR7 positive
    VEGFA 2055A>C
    ABCB1 mutation + VEGFA mutation
    CD20 positive
    ATM mutation
    TP53 mutation + CARD11 mutation + SMARCA4 mutation
    CCND1 overexpression
    HES1 overexpression
    MRD4 negative
    SOX11 expression
    CTLA4 overexpression
    ITK overexpression
    CCND1 expression
    ATM deletion
    ATM underexpression
    Chr t(11;14)
    IL2 elevation
    IL6 elevation
    TNFA elevation
    LY9 expression
    BTK C481S
    PIK3CG expression
    PIK3CD expression
    PIK3CB expression
    PIK3CA expression
    BCL2L1 overexpression
    CCND1 expression + CDK4 expression
    NOTCH1 mutation
    SAMHD1 mutation
    NRAS G13D
    PRMT5 overexpression + MTAP deletion
    MUC20 underexpression
    NLRC5 mutation
    B2M mutation
    CARD11 mutation
    MYC overexpression
    PD-L1 underexpression
    CDKN2A deletion
    CDKN2A deletion + MTAP deletion
    CDKN2A overexpression
    RB1 deletion
    ARID1B deletion
    DLGAP2 deletion
    BIRC3 mutation
    MCL1 overexpression
    MALT1 overexpression
    CD19 positive
    CD163 elevation
    CD19 expression
    HRD
    ROR1 overexpression
    ROR1 expression